249 related articles for article (PubMed ID: 15952926)
1. Gefitinib in non-small cell lung cancer.
Tamura K; Fukuoka M
Expert Opin Pharmacother; 2005 Jun; 6(6):985-93. PubMed ID: 15952926
[TBL] [Abstract][Full Text] [Related]
2. Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial--INTACT 2.
Herbst RS; Giaccone G; Schiller JH; Natale RB; Miller V; Manegold C; Scagliotti G; Rosell R; Oliff I; Reeves JA; Wolf MK; Krebs AD; Averbuch SD; Ochs JS; Grous J; Fandi A; Johnson DH
J Clin Oncol; 2004 Mar; 22(5):785-94. PubMed ID: 14990633
[TBL] [Abstract][Full Text] [Related]
3. Erlotinib and gefitinib for treating non-small cell lung cancer that has progressed following prior chemotherapy (review of NICE technology appraisals 162 and 175): a systematic review and economic evaluation.
Greenhalgh J; Bagust A; Boland A; Dwan K; Beale S; Hockenhull J; Proudlove C; Dundar Y; Richardson M; Dickson R; Mullard A; Marshall E
Health Technol Assess; 2015 Jun; 19(47):1-134. PubMed ID: 26134145
[TBL] [Abstract][Full Text] [Related]
4. Gefitinib: a review of its use in the treatment of locally advanced/metastatic non-small cell lung cancer.
Sanford M; Scott LJ
Drugs; 2009 Nov; 69(16):2303-28. PubMed ID: 19852530
[TBL] [Abstract][Full Text] [Related]
5. Gefitinib therapy for non-small cell lung cancer.
Birnbaum A; Ready N
Curr Treat Options Oncol; 2005 Jan; 6(1):75-81. PubMed ID: 15610717
[TBL] [Abstract][Full Text] [Related]
6. Gefitinib plus chemotherapy versus placebo plus chemotherapy in EGFR-mutation-positive non-small-cell lung cancer after progression on first-line gefitinib (IMPRESS): a phase 3 randomised trial.
Soria JC; Wu YL; Nakagawa K; Kim SW; Yang JJ; Ahn MJ; Wang J; Yang JC; Lu Y; Atagi S; Ponce S; Lee DH; Liu Y; Yoh K; Zhou JY; Shi X; Webster A; Jiang H; Mok TS
Lancet Oncol; 2015 Aug; 16(8):990-8. PubMed ID: 26159065
[TBL] [Abstract][Full Text] [Related]
7. [Molecular targeted therapy--non-small-cell lung cancer and gefitinib].
Shimizu J; Horio Y; Mitsudomi T
Gan To Kagaku Ryoho; 2005 Nov; 32(12):1879-85. PubMed ID: 16282720
[TBL] [Abstract][Full Text] [Related]
8. United States Food and Drug Administration Drug Approval summary: Gefitinib (ZD1839; Iressa) tablets.
Cohen MH; Williams GA; Sridhara R; Chen G; McGuinn WD; Morse D; Abraham S; Rahman A; Liang C; Lostritto R; Baird A; Pazdur R
Clin Cancer Res; 2004 Feb; 10(4):1212-8. PubMed ID: 14977817
[TBL] [Abstract][Full Text] [Related]
9. FDA drug approval summary: gefitinib (ZD1839) (Iressa) tablets.
Cohen MH; Williams GA; Sridhara R; Chen G; Pazdur R
Oncologist; 2003; 8(4):303-6. PubMed ID: 12897327
[TBL] [Abstract][Full Text] [Related]
10. Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase III trial--INTACT 1.
Giaccone G; Herbst RS; Manegold C; Scagliotti G; Rosell R; Miller V; Natale RB; Schiller JH; Von Pawel J; Pluzanska A; Gatzemeier U; Grous J; Ochs JS; Averbuch SD; Wolf MK; Rennie P; Fandi A; Johnson DH
J Clin Oncol; 2004 Mar; 22(5):777-84. PubMed ID: 14990632
[TBL] [Abstract][Full Text] [Related]
11. A review of the benefit-risk profile of gefitinib in Asian patients with advanced non-small-cell lung cancer.
Park K; Goto K
Curr Med Res Opin; 2006 Mar; 22(3):561-73. PubMed ID: 16574039
[TBL] [Abstract][Full Text] [Related]
12. Gefitinib (IRESSA) in patients of Asian origin with refractory advanced non-small cell lung cancer: subset analysis from the ISEL study.
Chang A; Parikh P; Thongprasert S; Tan EH; Perng RP; Ganzon D; Yang CH; Tsao CJ; Watkins C; Botwood N; Thatcher N
J Thorac Oncol; 2006 Oct; 1(8):847-55. PubMed ID: 17409969
[TBL] [Abstract][Full Text] [Related]
13. Activity of a specific inhibitor, gefitinib (Iressa, ZD1839), of epidermal growth factor receptor in refractory non-small-cell lung cancer.
Santoro A; Cavina R; Latteri F; Zucali PA; Ginanni V; Campagnoli E; Ferrari B; Morenghi E; Pedicini V; Roncalli M; Alloisio M; Ravasi G; Soto Parra HJ
Ann Oncol; 2004 Jan; 15(1):33-7. PubMed ID: 14679116
[TBL] [Abstract][Full Text] [Related]
14. [Gefitinib in the treatment of advanced non-small cell lung cancer].
Yang L; Liu XY; Fang J; An TT; Wu MN
Zhonghua Zhong Liu Za Zhi; 2006 Jun; 28(6):474-7. PubMed ID: 17152500
[TBL] [Abstract][Full Text] [Related]
15. Emerging role of gefitinib in the treatment of non-small-cell lung cancer (NSCLC).
Tiseo M; Bartolotti M; Gelsomino F; Bordi P
Drug Des Devel Ther; 2010 May; 4():81-98. PubMed ID: 20531963
[TBL] [Abstract][Full Text] [Related]
16. Gefitinib in patients with advanced non-small cell lung cancer (NSCLC): the expanded access protocol experience at the University of Pennsylvania.
Veronese ML; Algazy K; Bearn L; Eaby B; Alavi J; Evans T; Stevenson JP; Shults J
Cancer Invest; 2005; 23(4):296-302. PubMed ID: 16100941
[TBL] [Abstract][Full Text] [Related]
17. Gefitinib for the first-line treatment of locally advanced or metastatic non-small cell lung cancer.
Brown T; Boland A; Bagust A; Oyee J; Hockenhull J; Dundar Y; Dickson R; Ramani VS; Proudlove C
Health Technol Assess; 2010 Oct; 14(Suppl. 2):71-9. PubMed ID: 21047494
[TBL] [Abstract][Full Text] [Related]
18. A phase II trial of gefitinib monotherapy in chemotherapy-naïve patients of 75 years or older with advanced non-small cell lung cancer.
Ebi N; Semba H; Tokunaga SJ; Takayama K; Wataya H; Kuraki T; Yamamoto H; Akamine SJ; Okamoto I; Nakanishi Y;
J Thorac Oncol; 2008 Oct; 3(10):1166-71. PubMed ID: 18827614
[TBL] [Abstract][Full Text] [Related]
19. Epidermal growth factor receptor expression analysis in chemotherapy-naive patients with advanced non-small-cell lung cancer treated with gefitinib or placebo in combination with platinum-based chemotherapy.
Giaccone G; Iacona RB; Fandi A; Janas M; Ochs JS; Herbst RS; Johnson DH
J Cancer Res Clin Oncol; 2009 Mar; 135(3):467-76. PubMed ID: 18787840
[TBL] [Abstract][Full Text] [Related]
20. Gefitinib (ZD1839, Iressa) in non-small-cell lung cancer: a review of clinical trials from a daily practice perspective.
Barlési F; Tchouhadjian C; Doddoli C; Villani P; Greillier L; Kleisbauer JP; Thomas P; Astoul P
Fundam Clin Pharmacol; 2005 Jun; 19(3):385-93. PubMed ID: 15910663
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
